On December 20, 2014, Wang Yumin, the head of the national special supervision and evaluation team for major new drug discovery and theformer vice-minister of the Ministry of health of the general logistics department of the people's liberation army, Shi Yuankai, the member of the supervision and evaluation team and the vice-president of the tumor hospital of the Chinese Academy of Medical Sciences, Ai Chunbo, the director of the Ministry of science and technology of the Chinese Chemical Pharmaceutical Industry Association, Zheng yuguo, director of the China biotechnology development center, Li guanmin, director of the China Food and Dug Verification Research Institute, Wang Li, the chairman of the Chengdu Huaxi Haiqi Pharmaceutical Technology Company, and Chen Yancheng, the director of the major special office of the Ministry of Science and Technology, Wu peixin, the director of the major special department of the science and education department of the Health Planning Commission, and Science and Technology Department. They went to Shenzhen CHIPSCREEN BIOSCIENCES for an investigation and carried out on-the-spot research on the major scientific and technological projects undertaken by Shenzhen CHIPSCREEN BIOSCIENCES for " major new drug discovery".

Dr. Lu Xianping, the president and chief scientific officer of Shenzhen CHIPSCREEN BIOSCIENCES, reported to the special supervision and evaluation team the overall situation of the implementation and management of new drug special tasks, as well as the major progress of CHIPSCREEN BIOSCIENCES in researching original new drugs Chidamide, Chiglitazar, Theo Ronnie and other products, and summarized the development mode of enterprise " returnees scientific team + government support + venture capital". The evaluation team listened carefully to the report, thoroughly understood the relevant opinions andsuggestions of the enterprise regarding the implementation of the new drug special organization, conducted data inspection, and on-site inspected the construction of the enterprise's innovative drug incubation base.

The evaluation team highly praised the outstanding contribution made by Shenzhen CHIPSCREEN BIOSCIENCES in the field of original new drug research and development and fully affirmed the successful development mode of the enterprise. Evaluation team leader Wang Yumin believes that CHIPSCREEN BIOSCIENCES's achievements have inspired the evaluation team. in such a small enterprise with less than 100 personnel, after more than ten years of hard work and ten years of hard work, many aspects can be studied as typical cases of special support. Deputy director Li Fugui of Shenzhen Science and Technology Innovation Committee, who accompanied the investigation, also explained to the experts of the evaluation team the support policies of Shenzhen local government for enterprise innovation activities.